Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

2.52
-0.0800-3.08%
Post-market: 2.550.0300+1.19%16:21 EST
Volume:5.81M
Turnover:14.87M
Market Cap:1.00B
PE:-2.10
High:2.68
Open:2.66
Low:2.50
Close:2.60
52wk High:6.09
52wk Low:1.64
Shares:396.97M
Float Shares:304.00M
Volume Ratio:0.64
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1987
EPS(LYR):-1.2839
ROE:-53.89%
ROA:-27.12%
PB:1.42
PE(LYR):-1.96

Loading ...

Iovance Biotherapeutics Inc. published an update to their financial calendar

Reuters
·
Yesterday

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

GlobeNewswire
·
Yesterday

Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive?

Simply Wall St.
·
Feb 07

Iovance Biotherapeutics Reports Best-in-Class Real-World Response Rates for Amtagvi in Advanced Melanoma

Reuters
·
Feb 06

Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Feb 04

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jan 28

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 17

Iovance Biotherapeutics (IOVA) Receives a Buy from Wells Fargo

TIPRANKS
·
Jan 16

Assessing Iovance Biotherapeutics (IOVA) Valuation After Revenue Guidance And 1,000 Patient Milestone

Simply Wall St.
·
Jan 11

Iovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation

Reuters
·
Jan 09

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 20, 2025

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Nov 24, 2025

Iovance Biotherapeutics (IOVA) Gets a Buy from Barclays

TIPRANKS
·
Nov 24, 2025

Iovance Biotherapeutics Grants Stock Options to New Employees Under Amended Inducement Plan

Reuters
·
Nov 22, 2025

Stock Track | Iovance Biotherapeutics Soars 5.65% Pre-Market Despite Mixed Goldman Sachs Report

Stock Track
·
Nov 10, 2025

Iovance Biotherapeutics price target raised to $1.50 from $1 at Goldman Sachs

TIPRANKS
·
Nov 10, 2025

Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track
·
Nov 07, 2025

Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track
·
Nov 07, 2025

Stock Track | Iovance Biotherapeutics Plunges 5.19% Pre-market Following Chardan's Price Target Cut

Stock Track
·
Nov 07, 2025